ID   PIM1_HUMAN              Reviewed;         404 AA.
AC   P11309; Q38RT9; Q5T7H7; Q96RG3;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   06-DEC-2005, sequence version 3.
DT   12-APR-2017, entry version 204.
DE   RecName: Full=Serine/threonine-protein kinase pim-1;
DE            EC=2.7.11.1;
GN   Name=PIM1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 2).
RX   PubMed=2205533; DOI=10.1016/0378-1119(90)90195-W;
RA   Reeves R., Spies G.A., Kiefer M., Barr P.J., Power M.;
RT   "Primary structure of the putative human oncogene, pim-1.";
RL   Gene 90:303-307(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=3475233; DOI=10.1016/0378-1119(87)90352-0;
RA   Zakut-Houri R., Hazum S., Givol D., Telerman A.;
RT   "The cDNA sequence and gene analysis of the human pim oncogene.";
RL   Gene 54:105-111(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=3329709;
RA   Domen J., von Lindern M., Hermans A., Breuer M., Grosveld G.,
RA   Berns A.;
RT   "Comparison of the human and mouse PIM-1 cDNAs: nucleotide sequence
RT   and immunological identification of the in vitro synthesized PIM-1
RT   protein.";
RL   Oncogene Res. 1:103-112(1987).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=3429489; DOI=10.1002/jcb.240350204;
RA   Meeker T.C., Nagarajan L., Ar-Rushdi A., Croce C.M.;
RT   "Cloning and characterization of the human PIM-1 gene: a putative
RT   oncogene related to the protein kinases.";
RL   J. Cell. Biochem. 35:105-112(1987).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), ALTERNATIVE INITIATION, TISSUE
RP   SPECIFICITY, SUBCELLULAR LOCATION, INDUCTION, AND INTERACTION WITH
RP   BMX.
RX   PubMed=16186805; DOI=10.1038/sj.onc.1209058;
RA   Xie Y., Xu K., Dai B., Guo Z., Jiang T., Chen H., Qiu Y.;
RT   "The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase
RT   Etk/BMX and protects human prostate cancer cells from apoptosis
RT   induced by chemotherapeutic drugs.";
RL   Oncogene 25:70-78(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 92-293 (ISOFORM 2).
RX   PubMed=11460166; DOI=10.1038/35085588;
RA   Pasqualucci L., Neumeister P., Goossens T., Nanjangud G.,
RA   Chaganti R.S.K., Kuppers R., Dalla-Favera R.;
RT   "Hypermutation of multiple proto-oncogenes in B-cell diffuse large-
RT   cell lymphomas.";
RL   Nature 412:341-346(2001).
RN   [10]
RP   CHARACTERIZATION.
RX   PubMed=2837645; DOI=10.1128/MCB.8.4.1498;
RA   Telerman A., Amson R., Zakut-Houri R., Givol D.;
RT   "Identification of the human pim-1 gene product as a 33-kilodalton
RT   cytoplasmic protein with tyrosine kinase activity.";
RL   Mol. Cell. Biol. 8:1498-1503(1988).
RN   [11]
RP   FUNCTION, AND ALTERNATIVE INITIATION.
RX   PubMed=1825810;
RA   Saris C.J., Domen J., Berns A.;
RT   "The pim-1 oncogene encodes two related protein-serine/threonine
RT   kinases by alternative initiation at AUG and CUG.";
RL   EMBO J. 10:655-664(1991).
RN   [12]
RP   INTERACTION WITH CBX3, AND FUNCTION IN PHOSPHORYLATION OF CBX3.
RX   PubMed=10664448; DOI=10.1016/S0014-5793(00)01105-4;
RA   Koike N., Maita H., Taira T., Ariga H., Iguchi-Ariga S.M.M.;
RT   "Identification of heterochromatin protein 1 (HP1) as a
RT   phosphorylation target by Pim-1 kinase and the effect of
RT   phosphorylation on the transcriptional repression function of HP1.";
RL   FEBS Lett. 467:17-21(2000).
RN   [13]
RP   SUBCELLULAR LOCATION, FUNCTION IN PHOSPHORYLATION OF CDKN1A, AND
RP   INTERACTION WITH CDKN1A.
RX   PubMed=12431783; DOI=10.1016/S0167-4889(02)00347-6;
RA   Wang Z., Bhattacharya N., Mixter P.F., Wei W., Sedivy J.,
RA   Magnuson N.S.;
RT   "Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1
RT   kinase.";
RL   Biochim. Biophys. Acta 1593:45-55(2002).
RN   [14]
RP   SUBCELLULAR LOCATION.
RX   PubMed=12680209;
RA   Ionov Y., Le X., Tunquist B.J., Sweetenham J., Sachs T., Ryder J.,
RA   Johnson T., Lilly M.B., Kraft A.S.;
RT   "Pim-1 protein kinase is nuclear in Burkitt's lymphoma: nuclear
RT   localization is necessary for its biologic effects.";
RL   Anticancer Res. 23:167-178(2003).
RN   [15]
RP   INTERACTION WITH PPP2CA, PHOSPHORYLATION, AND UBIQUITINATION.
RX   PubMed=12473674; DOI=10.1074/jbc.M208246200;
RA   Losman J.A., Chen X.P., Vuong B.Q., Fay S., Rothman P.B.;
RT   "Protein phosphatase 2A regulates the stability of Pim protein
RT   kinases.";
RL   J. Biol. Chem. 278:4800-4805(2003).
RN   [16]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=15528381; DOI=10.4049/jimmunol.173.10.6409;
RA   Stout B.A., Bates M.E., Liu L.Y., Farrington N.N., Bertics P.J.;
RT   "IL-5 and granulocyte-macrophage colony-stimulating factor activate
RT   STAT3 and STAT5 and promote Pim-1 and cyclin D3 protein expression in
RT   human eosinophils.";
RL   J. Immunol. 173:6409-6417(2004).
RN   [17]
RP   UBIQUITINATION, INTERACTION WITH HSPCA AND HSP70, AND INDUCTION.
RX   PubMed=15798097; DOI=10.1158/1541-7786.MCR-04-0192;
RA   Shay K.P., Wang Z., Xing P.X., McKenzie I.F., Magnuson N.S.;
RT   "Pim-1 kinase stability is regulated by heat shock proteins and the
RT   ubiquitin-proteasome pathway.";
RL   Mol. Cancer Res. 3:170-181(2005).
RN   [18]
RP   FUNCTION IN PHOSPHORYLATION OF CDC25C, AND INTERACTION WITH CDC25C.
RX   PubMed=16356754; DOI=10.1016/j.biocel.2005.10.010;
RA   Bachmann M., Kosan C., Xing P.X., Montenarh M., Hoffmann I., Moroy T.;
RT   "The oncogenic serine/threonine kinase Pim-1 directly phosphorylates
RT   and activates the G2/M specific phosphatase Cdc25C.";
RL   Int. J. Biochem. Cell Biol. 38:430-443(2006).
RN   [19]
RP   FUNCTION IN CELL CYCLE PROGRESSION, INTERACTION WITH CDKN1B AND FOXO3,
RP   AND PHOSPHORYLATION OF CDKN1B AND FOXO3.
RX   PubMed=18593906; DOI=10.1158/0008-5472.CAN-08-0634;
RA   Morishita D., Katayama R., Sekimizu K., Tsuruo T., Fujita N.;
RT   "Pim kinases promote cell cycle progression by phosphorylating and
RT   down-regulating p27Kip1 at the transcriptional and posttranscriptional
RT   levels.";
RL   Cancer Res. 68:5076-5085(2008).
RN   [20]
RP   FUNCTION IN PHOSPHORYLATION OF MAP3K5, AND INTERACTION WITH MAP3K5.
RX   PubMed=19749799; DOI=10.1038/onc.2009.276;
RA   Gu J.J., Wang Z., Reeves R., Magnuson N.S.;
RT   "PIM1 phosphorylates and negatively regulates ASK1-mediated
RT   apoptosis.";
RL   Oncogene 28:4261-4271(2009).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-99, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) OF 124-396 IN COMPLEXES WITH
RP   ADENOSINE AND INHIBITORS STAUROSPORINE AND LY294002, CATALYTIC
RP   ACTIVITY, COFACTOR, ENZYME REGULATION, IDENTIFICATION BY MASS
RP   SPECTROMETRY, AND PHOSPHORYLATION AT SER-99; THR-114; SER-189 AND
RP   SER-352.
RX   PubMed=15657054; DOI=10.1074/jbc.M413155200;
RA   Jacobs M.D., Black J., Futer O., Swenson L., Hare B., Fleming M.,
RA   Saxena K.;
RT   "Pim-1 ligand-bound structures reveal the mechanism of
RT   serine/threonine kinase inhibition by LY294002.";
RL   J. Biol. Chem. 280:13728-13734(2005).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 105-404 OF APOPROTEIN AND IN
RP   COMPLEX WITH AMP-PNP, CATALYTIC ACTIVITY, COFACTOR, AND ENZYME
RP   REGULATION.
RX   PubMed=15525646; DOI=10.1074/jbc.M409123200;
RA   Qian K.C., Wang L., Hickey E.R., Studts J., Barringer K., Peng C.,
RA   Kronkaitis A., Li J., White A., Mische S., Farmer B.;
RT   "Structural basis of constitutive activity and a unique nucleotide
RT   binding mode of human Pim-1 kinase.";
RL   J. Biol. Chem. 280:6130-6137(2005).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 120-404 OF APOPROTEIN AND IN
RP   COMPLEXES WITH AMP-PNP AND INHIBITORS, PARTIAL PROTEIN SEQUENCE,
RP   CATALYTIC ACTIVITY, ENZYME REGULATION, COFACTOR, AND MUTAGENESIS OF
RP   HIS-159; PRO-172; ASN-173 AND LEU-284.
RX   PubMed=15808862; DOI=10.1016/j.jmb.2005.02.039;
RA   Kumar A., Mandiyan V., Suzuki Y., Zhang C., Rice J., Tsai J.,
RA   Artis D.R., Ibrahim P., Bremer R.;
RT   "Crystal structures of proto-oncogene kinase Pim1: a target of
RT   aberrant somatic hypermutations in diffuse large cell lymphoma.";
RL   J. Mol. Biol. 348:183-193(2005).
RN   [25]
RP   VARIANTS [LARGE SCALE ANALYSIS] HIS-144; GLN-215; LYS-226 AND ASP-233.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Proto-oncogene with serine/threonine kinase activity
CC       involved in cell survival and cell proliferation and thus
CC       providing a selective advantage in tumorigenesis. Exerts its
CC       oncogenic activity through: the regulation of MYC transcriptional
CC       activity, the regulation of cell cycle progression and by
CC       phosphorylation and inhibition of proapoptotic proteins (BAD,
CC       MAP3K5, FOXO3). Phosphorylation of MYC leads to an increase of MYC
CC       protein stability and thereby an increase of transcriptional
CC       activity. The stabilization of MYC exerted by PIM1 might explain
CC       partly the strong synergism between these two oncogenes in
CC       tumorigenesis. Mediates survival signaling through phosphorylation
CC       of BAD, which induces release of the anti-apoptotic protein Bcl-
CC       X(L)/BCL2L1. Phosphorylation of MAP3K5, an other proapoptotic
CC       protein, by PIM1, significantly decreases MAP3K5 kinase activity
CC       and inhibits MAP3K5-mediated phosphorylation of JNK and
CC       JNK/p38MAPK subsequently reducing caspase-3 activation and cell
CC       apoptosis. Stimulates cell cycle progression at the G1-S and G2-M
CC       transitions by phosphorylation of CDC25A and CDC25C.
CC       Phosphorylation of CDKN1A, a regulator of cell cycle progression
CC       at G1, results in the relocation of CDKN1A to the cytoplasm and
CC       enhanced CDKN1A protein stability. Promote cell cycle progression
CC       and tumorigenesis by down-regulating expression of a regulator of
CC       cell cycle progression, CDKN1B, at both transcriptional and post-
CC       translational levels. Phosphorylation of CDKN1B,induces 14-3-3-
CC       proteins binding, nuclear export and proteasome-dependent
CC       degradation. May affect the structure or silencing of chromatin by
CC       phosphorylating HP1 gamma/CBX3. Acts also as a regulator of homing
CC       and migration of bone marrow cells involving functional
CC       interaction with the CXCL12-CXCR4 signaling axis.
CC       {ECO:0000269|PubMed:10664448, ECO:0000269|PubMed:12431783,
CC       ECO:0000269|PubMed:15528381, ECO:0000269|PubMed:16356754,
CC       ECO:0000269|PubMed:1825810, ECO:0000269|PubMed:18593906,
CC       ECO:0000269|PubMed:19749799}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC       {ECO:0000269|PubMed:15525646, ECO:0000269|PubMed:15657054,
CC       ECO:0000269|PubMed:15808862}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:15525646,
CC         ECO:0000269|PubMed:15657054, ECO:0000269|PubMed:15808862};
CC   -!- SUBUNIT: Isoform 2 is isolated as a monomer whereas isoform 1
CC       complexes with other proteins (By similarity). Binds to RP9 (By
CC       similarity). Isoform 1, but not isoform 2, binds BMX. Isoform 2
CC       interacts with CDKN1B and FOXO3. Interacts with BAD. Interacts
CC       with PPP2CA; this interaction promotes dephosphorylation of PIM1,
CC       ubiquitination and proteasomal degradation (By similarity).
CC       Interacts with HSP90, this interaction stabilizes PIM1 protein
CC       levels. Interacts (ubiquitinated form) with HSP70 and promotes its
CC       proteosomal degradation. Interacts with CDKN1A. Interacts with
CC       CDC25C. Interacts (via N-terminal 96 residues) with CDC25A (By
CC       similarity). Interacts with MAP3K5. Interacts with MYC (By
CC       similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       Q9UNQ0:ABCG2; NbExp=9; IntAct=EBI-1018629, EBI-1569435;
CC       Q8N9N5:BANP; NbExp=3; IntAct=EBI-696621, EBI-744695;
CC       Q8N7W2-2:BEND7; NbExp=3; IntAct=EBI-696621, EBI-10181188;
CC       P51813:BMX; NbExp=4; IntAct=EBI-696621, EBI-696657;
CC       P46527:CDKN1B; NbExp=2; IntAct=EBI-696621, EBI-519280;
CC       P07954:FH; NbExp=3; IntAct=EBI-696621, EBI-1050358;
CC       O43524:FOXO3; NbExp=2; IntAct=EBI-696621, EBI-1644164;
CC       Q9BZS1-1:FOXP3; NbExp=3; IntAct=EBI-1018633, EBI-9695448;
CC       P51116:FXR2; NbExp=3; IntAct=EBI-696621, EBI-740459;
CC       Q96MH2:HEXIM2; NbExp=3; IntAct=EBI-696621, EBI-5460660;
CC       Q5T203:NHLH1; NbExp=3; IntAct=EBI-696621, EBI-10197511;
CC       P39019:RPS19; NbExp=7; IntAct=EBI-696621, EBI-354451;
CC       G5E9B5:TFPT; NbExp=3; IntAct=EBI-696621, EBI-10178002;
CC       Q9Y2K1:ZBTB1; NbExp=3; IntAct=EBI-696621, EBI-2682961;
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cytoplasm. Nucleus.
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Cell membrane.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative initiation; Named isoforms=2;
CC       Name=1;
CC         IsoId=P11309-1; Sequence=Displayed;
CC         Note=Initiates from CTG codon.;
CC       Name=2;
CC         IsoId=P11309-2; Sequence=VSP_016530;
CC   -!- TISSUE SPECIFICITY: Expressed primarily in cells of the
CC       hematopoietic and germline lineages. Isoform 1 and isoform 2 are
CC       both expressed in prostate cancer cell lines.
CC       {ECO:0000269|PubMed:16186805}.
CC   -!- INDUCTION: Strongly induced in leukocytes by the JAK/STAT pathway
CC       in response to cytokines. Induced by different cellular stresses,
CC       heat shock and cytotoxic agents. {ECO:0000269|PubMed:15528381,
CC       ECO:0000269|PubMed:15798097, ECO:0000269|PubMed:16186805}.
CC   -!- PTM: Autophosphorylated on both serine/threonine and tyrosine
CC       residues. Phosphorylated. Interaction with PPP2CA promotes
CC       dephosphorylation. {ECO:0000269|PubMed:12473674,
CC       ECO:0000269|PubMed:15657054, ECO:0000269|PubMed:18593906}.
CC   -!- PTM: Ubiquitinated, leading to proteasomal degradation.
CC       {ECO:0000269|PubMed:12473674, ECO:0000269|PubMed:15798097}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK
CC       Ser/Thr protein kinase family. PIM subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PIM1ID261.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M27903; AAA60090.1; -; Genomic_DNA.
DR   EMBL; M16750; AAA60089.1; -; mRNA.
DR   EMBL; M54915; AAA36447.1; -; mRNA.
DR   EMBL; M24779; AAA81553.1; -; mRNA.
DR   EMBL; DQ022562; AAY87461.1; -; mRNA.
DR   EMBL; AL353579; CAI20316.1; -; Genomic_DNA.
DR   EMBL; CH471081; EAX03934.1; -; Genomic_DNA.
DR   EMBL; BC020224; AAH20224.1; -; mRNA.
DR   EMBL; AF386792; AAK70871.1; -; Genomic_DNA.
DR   CCDS; CCDS4830.1; -. [P11309-2]
DR   PIR; JU0327; TVHUP1.
DR   RefSeq; NP_001230115.1; NM_001243186.1. [P11309-1]
DR   RefSeq; NP_002639.1; NM_002648.3. [P11309-2]
DR   UniGene; Hs.81170; -.
DR   PDB; 1XQZ; X-ray; 2.10 A; A=105-404.
DR   PDB; 1XR1; X-ray; 2.10 A; A=105-404.
DR   PDB; 1XWS; X-ray; 1.80 A; A=92-404.
DR   PDB; 1YHS; X-ray; 2.15 A; A=124-396.
DR   PDB; 1YI3; X-ray; 2.50 A; A=124-396.
DR   PDB; 1YI4; X-ray; 2.40 A; A=124-396.
DR   PDB; 1YWV; X-ray; 2.00 A; A=120-404.
DR   PDB; 1YXS; X-ray; 2.20 A; A=120-404.
DR   PDB; 1YXT; X-ray; 2.00 A; A=120-404.
DR   PDB; 1YXU; X-ray; 2.24 A; A/B/C/D=120-404.
DR   PDB; 1YXV; X-ray; 2.00 A; A=120-404.
DR   PDB; 1YXX; X-ray; 2.00 A; A=120-404.
DR   PDB; 2BIK; X-ray; 1.80 A; B=92-404.
DR   PDB; 2BIL; X-ray; 2.55 A; B=92-404.
DR   PDB; 2BZH; X-ray; 1.90 A; B=92-404.
DR   PDB; 2BZI; X-ray; 1.90 A; B=92-404.
DR   PDB; 2BZJ; X-ray; 2.05 A; A=92-404.
DR   PDB; 2BZK; X-ray; 2.45 A; B=92-404.
DR   PDB; 2C3I; X-ray; 1.90 A; B=92-404.
DR   PDB; 2J2I; X-ray; 1.90 A; B=92-403.
DR   PDB; 2O3P; X-ray; 2.24 A; A=120-404.
DR   PDB; 2O63; X-ray; 2.00 A; A=120-404.
DR   PDB; 2O64; X-ray; 2.44 A; A=120-404.
DR   PDB; 2O65; X-ray; 2.85 A; A=120-404.
DR   PDB; 2OBJ; X-ray; 2.50 A; A=92-404.
DR   PDB; 2OI4; X-ray; 2.20 A; X=92-404.
DR   PDB; 2XIX; X-ray; 2.40 A; A=105-404.
DR   PDB; 2XIY; X-ray; 2.20 A; A=105-404.
DR   PDB; 2XIZ; X-ray; 2.21 A; A=105-404.
DR   PDB; 2XJ0; X-ray; 3.10 A; A=105-404.
DR   PDB; 2XJ1; X-ray; 2.13 A; A=105-404.
DR   PDB; 2XJ2; X-ray; 2.20 A; A=105-404.
DR   PDB; 3A99; X-ray; 1.60 A; A=106-404.
DR   PDB; 3BGP; X-ray; 2.80 A; A=92-404.
DR   PDB; 3BGQ; X-ray; 2.00 A; A=92-404.
DR   PDB; 3BGZ; X-ray; 2.40 A; A=92-404.
DR   PDB; 3BWF; X-ray; 2.35 A; A=92-404.
DR   PDB; 3C4E; X-ray; 1.98 A; A/B/C/D=124-396.
DR   PDB; 3CXW; X-ray; 2.10 A; A=92-404.
DR   PDB; 3CY2; X-ray; 2.01 A; A=92-404.
DR   PDB; 3CY3; X-ray; 2.15 A; A=92-404.
DR   PDB; 3DCV; X-ray; 2.70 A; A=93-404.
DR   PDB; 3F2A; X-ray; 1.90 A; A=105-404.
DR   PDB; 3JPV; X-ray; 2.35 A; A=92-403.
DR   PDB; 3JXW; X-ray; 2.80 A; A=120-404.
DR   PDB; 3JY0; X-ray; 2.40 A; A=120-404.
DR   PDB; 3JYA; X-ray; 2.10 A; A=120-404.
DR   PDB; 3MA3; X-ray; 2.30 A; A=93-403.
DR   PDB; 3QF9; X-ray; 2.20 A; A=92-403.
DR   PDB; 3R00; X-ray; 2.10 A; A=120-404.
DR   PDB; 3R01; X-ray; 2.60 A; A=120-404.
DR   PDB; 3R02; X-ray; 1.95 A; A=120-404.
DR   PDB; 3R04; X-ray; 1.70 A; A=120-404.
DR   PDB; 3T9I; X-ray; 2.60 A; A=93-404.
DR   PDB; 3UIX; X-ray; 2.20 A; A=120-404.
DR   PDB; 3UMW; X-ray; 2.08 A; A=120-404.
DR   PDB; 3UMX; X-ray; 2.55 A; A=120-404.
DR   PDB; 3VBQ; X-ray; 1.85 A; A=120-404.
DR   PDB; 3VBT; X-ray; 2.23 A; A=120-404.
DR   PDB; 3VBV; X-ray; 2.08 A; A=120-404.
DR   PDB; 3VBW; X-ray; 2.48 A; A=120-404.
DR   PDB; 3VBX; X-ray; 2.03 A; A=120-404.
DR   PDB; 3VBY; X-ray; 2.27 A; A=120-404.
DR   PDB; 3VC4; X-ray; 2.23 A; A=120-404.
DR   PDB; 3WE8; X-ray; 1.95 A; A=124-396.
DR   PDB; 4A7C; X-ray; 2.30 A; A=121-404.
DR   PDB; 4ALU; X-ray; 2.60 A; A=93-404.
DR   PDB; 4ALV; X-ray; 2.59 A; A=93-404.
DR   PDB; 4ALW; X-ray; 1.92 A; A=93-404.
DR   PDB; 4AS0; X-ray; 2.30 A; A=124-396.
DR   PDB; 4BZN; X-ray; 1.90 A; A=93-404.
DR   PDB; 4BZO; X-ray; 2.10 A; A=93-404.
DR   PDB; 4DTK; X-ray; 1.86 A; A=121-396.
DR   PDB; 4ENX; X-ray; 2.80 A; A=120-404.
DR   PDB; 4ENY; X-ray; 2.80 A; A=120-404.
DR   PDB; 4GW8; X-ray; 2.00 A; A=92-403.
DR   PDB; 4I41; X-ray; 2.70 A; A=120-396.
DR   PDB; 4IAA; X-ray; 2.85 A; A=120-404.
DR   PDB; 4JX3; X-ray; 2.50 A; A=92-404.
DR   PDB; 4JX7; X-ray; 2.40 A; A=92-404.
DR   PDB; 4K0Y; X-ray; 1.95 A; A=124-397.
DR   PDB; 4K18; X-ray; 2.05 A; A=123-399.
DR   PDB; 4K1B; X-ray; 2.08 A; A=124-396.
DR   PDB; 4LL5; X-ray; 2.00 A; A=120-404.
DR   PDB; 4LM5; X-ray; 2.25 A; A=120-404.
DR   PDB; 4LMU; X-ray; 2.38 A; A=120-404.
DR   PDB; 4MBI; X-ray; 2.30 A; A=120-404.
DR   PDB; 4MBL; X-ray; 2.60 A; A=120-404.
DR   PDB; 4MED; X-ray; 2.80 A; A=120-404.
DR   PDB; 4MTA; X-ray; 2.20 A; A=119-404.
DR   PDB; 4N6Y; X-ray; 2.60 A; A=93-404.
DR   PDB; 4N6Z; X-ray; 2.20 A; A=93-404.
DR   PDB; 4N70; X-ray; 2.10 A; A=93-404.
DR   PDB; 4RBL; X-ray; 2.55 A; A=120-404.
DR   PDB; 4RC2; X-ray; 2.10 A; A=120-404.
DR   PDB; 4RC3; X-ray; 2.34 A; A=120-404.
DR   PDB; 4RC4; X-ray; 2.65 A; A=120-404.
DR   PDB; 4RPV; X-ray; 3.05 A; A=1-404.
DR   PDB; 4TY1; X-ray; 2.70 A; A=124-396.
DR   PDB; 4WRS; X-ray; 2.20 A; A=124-396.
DR   PDB; 4WSY; X-ray; 2.30 A; A=124-396.
DR   PDB; 4WT6; X-ray; 2.30 A; A=124-396.
DR   PDB; 4XH6; X-ray; 2.04 A; A=120-404.
DR   PDB; 4XHK; X-ray; 1.90 A; B=92-404.
DR   PDB; 5C1Q; X-ray; 3.00 A; B=120-404.
DR   PDB; 5DGZ; X-ray; 2.50 A; A=120-404.
DR   PDB; 5DHJ; X-ray; 2.46 A; A=120-404.
DR   PDB; 5DIA; X-ray; 1.96 A; A=120-404.
DR   PDB; 5DWR; X-ray; 2.00 A; A=93-404.
DR   PDB; 5EOL; X-ray; 2.20 A; A=124-396.
DR   PDB; 5IIS; X-ray; 2.10 A; A=123-399.
DR   PDB; 5IPJ; X-ray; 2.10 A; A=124-396.
DR   PDB; 5KZI; X-ray; 2.10 A; A=124-396.
DR   PDBsum; 1XQZ; -.
DR   PDBsum; 1XR1; -.
DR   PDBsum; 1XWS; -.
DR   PDBsum; 1YHS; -.
DR   PDBsum; 1YI3; -.
DR   PDBsum; 1YI4; -.
DR   PDBsum; 1YWV; -.
DR   PDBsum; 1YXS; -.
DR   PDBsum; 1YXT; -.
DR   PDBsum; 1YXU; -.
DR   PDBsum; 1YXV; -.
DR   PDBsum; 1YXX; -.
DR   PDBsum; 2BIK; -.
DR   PDBsum; 2BIL; -.
DR   PDBsum; 2BZH; -.
DR   PDBsum; 2BZI; -.
DR   PDBsum; 2BZJ; -.
DR   PDBsum; 2BZK; -.
DR   PDBsum; 2C3I; -.
DR   PDBsum; 2J2I; -.
DR   PDBsum; 2O3P; -.
DR   PDBsum; 2O63; -.
DR   PDBsum; 2O64; -.
DR   PDBsum; 2O65; -.
DR   PDBsum; 2OBJ; -.
DR   PDBsum; 2OI4; -.
DR   PDBsum; 2XIX; -.
DR   PDBsum; 2XIY; -.
DR   PDBsum; 2XIZ; -.
DR   PDBsum; 2XJ0; -.
DR   PDBsum; 2XJ1; -.
DR   PDBsum; 2XJ2; -.
DR   PDBsum; 3A99; -.
DR   PDBsum; 3BGP; -.
DR   PDBsum; 3BGQ; -.
DR   PDBsum; 3BGZ; -.
DR   PDBsum; 3BWF; -.
DR   PDBsum; 3C4E; -.
DR   PDBsum; 3CXW; -.
DR   PDBsum; 3CY2; -.
DR   PDBsum; 3CY3; -.
DR   PDBsum; 3DCV; -.
DR   PDBsum; 3F2A; -.
DR   PDBsum; 3JPV; -.
DR   PDBsum; 3JXW; -.
DR   PDBsum; 3JY0; -.
DR   PDBsum; 3JYA; -.
DR   PDBsum; 3MA3; -.
DR   PDBsum; 3QF9; -.
DR   PDBsum; 3R00; -.
DR   PDBsum; 3R01; -.
DR   PDBsum; 3R02; -.
DR   PDBsum; 3R04; -.
DR   PDBsum; 3T9I; -.
DR   PDBsum; 3UIX; -.
DR   PDBsum; 3UMW; -.
DR   PDBsum; 3UMX; -.
DR   PDBsum; 3VBQ; -.
DR   PDBsum; 3VBT; -.
DR   PDBsum; 3VBV; -.
DR   PDBsum; 3VBW; -.
DR   PDBsum; 3VBX; -.
DR   PDBsum; 3VBY; -.
DR   PDBsum; 3VC4; -.
DR   PDBsum; 3WE8; -.
DR   PDBsum; 4A7C; -.
DR   PDBsum; 4ALU; -.
DR   PDBsum; 4ALV; -.
DR   PDBsum; 4ALW; -.
DR   PDBsum; 4AS0; -.
DR   PDBsum; 4BZN; -.
DR   PDBsum; 4BZO; -.
DR   PDBsum; 4DTK; -.
DR   PDBsum; 4ENX; -.
DR   PDBsum; 4ENY; -.
DR   PDBsum; 4GW8; -.
DR   PDBsum; 4I41; -.
DR   PDBsum; 4IAA; -.
DR   PDBsum; 4JX3; -.
DR   PDBsum; 4JX7; -.
DR   PDBsum; 4K0Y; -.
DR   PDBsum; 4K18; -.
DR   PDBsum; 4K1B; -.
DR   PDBsum; 4LL5; -.
DR   PDBsum; 4LM5; -.
DR   PDBsum; 4LMU; -.
DR   PDBsum; 4MBI; -.
DR   PDBsum; 4MBL; -.
DR   PDBsum; 4MED; -.
DR   PDBsum; 4MTA; -.
DR   PDBsum; 4N6Y; -.
DR   PDBsum; 4N6Z; -.
DR   PDBsum; 4N70; -.
DR   PDBsum; 4RBL; -.
DR   PDBsum; 4RC2; -.
DR   PDBsum; 4RC3; -.
DR   PDBsum; 4RC4; -.
DR   PDBsum; 4RPV; -.
DR   PDBsum; 4TY1; -.
DR   PDBsum; 4WRS; -.
DR   PDBsum; 4WSY; -.
DR   PDBsum; 4WT6; -.
DR   PDBsum; 4XH6; -.
DR   PDBsum; 4XHK; -.
DR   PDBsum; 5C1Q; -.
DR   PDBsum; 5DGZ; -.
DR   PDBsum; 5DHJ; -.
DR   PDBsum; 5DIA; -.
DR   PDBsum; 5DWR; -.
DR   PDBsum; 5EOL; -.
DR   PDBsum; 5IIS; -.
DR   PDBsum; 5IPJ; -.
DR   PDBsum; 5KZI; -.
DR   DisProt; DP00322; -.
DR   ProteinModelPortal; P11309; -.
DR   SMR; P11309; -.
DR   BioGrid; 111310; 41.
DR   IntAct; P11309; 19.
DR   MINT; MINT-1412755; -.
DR   STRING; 9606.ENSP00000362608; -.
DR   BindingDB; P11309; -.
DR   ChEMBL; CHEMBL2147; -.
DR   DrugBank; DB03650; (3e)-3-[(4-Hydroxyphenyl)Imino]-1h-Indol-2(3h)-One.
DR   DrugBank; DB02656; 2-(4-Morpholinyl)-8-Phenyl-4h-1-Benzopyran-4-One.
DR   DrugBank; DB07151; 4-(4-hydroxy-3-methylphenyl)-6-phenylpyrimidin-2(5H)-one.
DR   DrugBank; DB00131; Adenosine monophosphate.
DR   DrugBank; DB04715; IMIDAZOPYRIDAZIN 1.
DR   DrugBank; DB04395; Phosphoaminophosphonic Acid-Adenylate Ester.
DR   DrugBank; DB04522; Phosphonoserine.
DR   DrugBank; DB04216; Quercetin.
DR   DrugBank; DB03777; Rbt205 Inhibitor.
DR   DrugBank; DB02010; Staurosporine.
DR   GuidetoPHARMACOLOGY; 2158; -.
DR   iPTMnet; P11309; -.
DR   PhosphoSitePlus; P11309; -.
DR   BioMuta; PIM1; -.
DR   DMDM; 83305339; -.
DR   MaxQB; P11309; -.
DR   PaxDb; P11309; -.
DR   PeptideAtlas; P11309; -.
DR   PRIDE; P11309; -.
DR   DNASU; 5292; -.
DR   Ensembl; ENST00000373509; ENSP00000362608; ENSG00000137193. [P11309-2]
DR   GeneID; 5292; -.
DR   KEGG; hsa:5292; -.
DR   UCSC; uc003onk.4; human. [P11309-1]
DR   CTD; 5292; -.
DR   DisGeNET; 5292; -.
DR   GeneCards; PIM1; -.
DR   HGNC; HGNC:8986; PIM1.
DR   HPA; CAB017040; -.
DR   HPA; HPA003941; -.
DR   MIM; 164960; gene.
DR   neXtProt; NX_P11309; -.
DR   OpenTargets; ENSG00000137193; -.
DR   PharmGKB; PA33318; -.
DR   eggNOG; KOG0583; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000119045; -.
DR   HOGENOM; HOG000231357; -.
DR   HOVERGEN; HBG106681; -.
DR   InParanoid; P11309; -.
DR   KO; K04702; -.
DR   OMA; KDTIYTD; -.
DR   OrthoDB; EOG091G0IMW; -.
DR   PhylomeDB; P11309; -.
DR   TreeFam; TF320810; -.
DR   Reactome; R-HSA-6785807; Interleukin-4 and 13 signaling.
DR   SignaLink; P11309; -.
DR   SIGNOR; P11309; -.
DR   ChiTaRS; PIM1; human.
DR   EvolutionaryTrace; P11309; -.
DR   GeneWiki; PIM1; -.
DR   GenomeRNAi; 5292; -.
DR   PRO; PR:P11309; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000137193; -.
DR   CleanEx; HS_PIM1; -.
DR   ExpressionAtlas; P11309; baseline and differential.
DR   Genevisible; P11309; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0030145; F:manganese ion binding; IDA:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0043024; F:ribosomal small subunit binding; IPI:UniProtKB.
DR   GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0008283; P:cell proliferation; IDA:UniProtKB.
DR   GO; GO:0030212; P:hyaluronan metabolic process; IEA:Ensembl.
DR   GO; GO:0007275; P:multicellular organism development; TAS:ProtInc.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0043433; P:negative regulation of sequence-specific DNA binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0060045; P:positive regulation of cardiac muscle cell proliferation; IDA:BHF-UCL.
DR   GO; GO:1905062; P:positive regulation of cardioblast proliferation; IDA:BHF-UCL.
DR   GO; GO:0031659; P:positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle; IDA:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0007346; P:regulation of mitotic cell cycle; IBA:GO_Central.
DR   GO; GO:0070561; P:vitamin D receptor signaling pathway; IMP:CACAO.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR017348; PIM1/2/3.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   PIRSF; PIRSF037993; STPK_Pim-1; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative initiation; Apoptosis; ATP-binding;
KW   Cell cycle; Cell membrane; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Kinase; Magnesium; Membrane; Metal-binding;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Proto-oncogene; Reference proteome; Serine/threonine-protein kinase;
KW   Transferase; Ubl conjugation.
FT   CHAIN         1    404       Serine/threonine-protein kinase pim-1.
FT                                /FTId=PRO_0000043349.
FT   DOMAIN      129    381       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     135    143       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    258    258       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     158    158       ATP.
FT   BINDING     212    212       ATP; via carbonyl oxygen.
FT   BINDING     219    219       ATP.
FT   MOD_RES      99     99       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:15657054}.
FT   MOD_RES     114    114       Phosphothreonine.
FT                                {ECO:0000269|PubMed:15657054}.
FT   MOD_RES     189    189       Phosphoserine.
FT                                {ECO:0000269|PubMed:15657054}.
FT   MOD_RES     352    352       Phosphoserine.
FT                                {ECO:0000269|PubMed:15657054}.
FT   VAR_SEQ       1     91       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:3329709,
FT                                ECO:0000303|PubMed:3429489,
FT                                ECO:0000303|PubMed:3475233}.
FT                                /FTId=VSP_016530.
FT   VARIANT     144    144       Y -> H (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041004.
FT   VARIANT     215    215       E -> Q. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041005.
FT   VARIANT     226    226       E -> K. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041006.
FT   VARIANT     233    233       E -> D. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041007.
FT   MUTAGEN     159    159       H->Y: Increased kinase activity.
FT                                {ECO:0000269|PubMed:15808862}.
FT   MUTAGEN     172    172       P->S: Decreased kinase activity.
FT                                {ECO:0000269|PubMed:15808862}.
FT   MUTAGEN     173    173       N->K: Decreased kinase activity.
FT                                {ECO:0000269|PubMed:15808862}.
FT   MUTAGEN     284    284       L->F: Decreased kinase activity.
FT                                {ECO:0000269|PubMed:15808862}.
FT   CONFLICT    106    107       AP -> RA (in Ref. 2; AAA60089).
FT                                {ECO:0000305}.
FT   TURN        126    128       {ECO:0000244|PDB:3A99}.
FT   STRAND      129    134       {ECO:0000244|PDB:3A99}.
FT   STRAND      136    140       {ECO:0000244|PDB:3A99}.
FT   STRAND      142    148       {ECO:0000244|PDB:3A99}.
FT   TURN        149    151       {ECO:0000244|PDB:3A99}.
FT   STRAND      154    161       {ECO:0000244|PDB:3A99}.
FT   HELIX       162    164       {ECO:0000244|PDB:3A99}.
FT   STRAND      168    170       {ECO:0000244|PDB:3A99}.
FT   TURN        172    174       {ECO:0000244|PDB:3C4E}.
FT   STRAND      176    178       {ECO:0000244|PDB:3A99}.
FT   HELIX       179    187       {ECO:0000244|PDB:3A99}.
FT   STRAND      189    191       {ECO:0000244|PDB:3A99}.
FT   STRAND      192    194       {ECO:0000244|PDB:3VBQ}.
FT   STRAND      197    202       {ECO:0000244|PDB:3A99}.
FT   STRAND      204    212       {ECO:0000244|PDB:3A99}.
FT   STRAND      215    219       {ECO:0000244|PDB:3A99}.
FT   HELIX       220    227       {ECO:0000244|PDB:3A99}.
FT   HELIX       232    251       {ECO:0000244|PDB:3A99}.
FT   HELIX       261    263       {ECO:0000244|PDB:3A99}.
FT   STRAND      264    267       {ECO:0000244|PDB:3A99}.
FT   TURN        268    271       {ECO:0000244|PDB:3A99}.
FT   STRAND      272    275       {ECO:0000244|PDB:3A99}.
FT   HELIX       278    280       {ECO:0000244|PDB:4ALW}.
FT   HELIX       296    298       {ECO:0000244|PDB:3A99}.
FT   HELIX       301    306       {ECO:0000244|PDB:3A99}.
FT   HELIX       311    328       {ECO:0000244|PDB:3A99}.
FT   HELIX       336    341       {ECO:0000244|PDB:3A99}.
FT   HELIX       352    361       {ECO:0000244|PDB:3A99}.
FT   HELIX       366    368       {ECO:0000244|PDB:3A99}.
FT   HELIX       372    376       {ECO:0000244|PDB:3A99}.
FT   HELIX       379    381       {ECO:0000244|PDB:3A99}.
FT   HELIX       387    394       {ECO:0000244|PDB:3A99}.
FT   TURN        395    398       {ECO:0000244|PDB:3F2A}.
SQ   SEQUENCE   404 AA;  45412 MW;  18C421B7CFF87818 CRC64;
     MPHEPHEPLT PPFSALPDPA GAPSRRQSRQ RPQLSSDSPS AFRASRSHSR NATRSHSHSH
     SPRHSLRHSP GSGSCGSSSG HRPCADILEV GMLLSKINSL AHLRAAPCND LHATKLAPGK
     EKEPLESQYQ VGPLLGSGGF GSVYSGIRVS DNLPVAIKHV EKDRISDWGE LPNGTRVPME
     VVLLKKVSSG FSGVIRLLDW FERPDSFVLI LERPEPVQDL FDFITERGAL QEELARSFFW
     QVLEAVRHCH NCGVLHRDIK DENILIDLNR GELKLIDFGS GALLKDTVYT DFDGTRVYSP
     PEWIRYHRYH GRSAAVWSLG ILLYDMVCGD IPFEHDEEII RGQVFFRQRV SSECQHLIRW
     CLALRPSDRP TFEEIQNHPW MQDVLLPQET AEIHLHSLSP GPSK
//
